Prostaglandins & other Lipid Mediators: A new phase, a new team

Prostaglandins and Other Lipid Mediators

Volumn 73, Issue 1-2, 2004, Pages 1-2

  Hla, Timothy ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPID; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

CELL COMMUNICATION; CELL MEMBRANE; EDITORIAL; PUBLICATION; SCIENTIFIC LITERATURE; STAFF;

COMPUTER COMMUNICATION NETWORKS; EICOSANOIDS; LEUKOTRIENES; PLATELET ACTIVATING FACTOR; PROSTAGLANDINS; PUBLICATIONS; RESEARCH; THROMBOXANES;

EID: 1842453358     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2003.11.001     Document Type: Editorial

References (3)

1. Gryglewski R.J., Bunting S., Moncada S., Flower R.J., Vane J.R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins. 12:1976;685-713.
2. Whittaker N., Bunting S., Salmon J., Moncada S., Vane J.R., Johnson R.A.et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. 12:1976;915-928.
3. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:1994;55-59.